**About the Editors**

#### **Olesja Bondarenko**

Olesja Bondarenko is a senior researcher and team leader at the National Institute of Chemical Physics and Biophysics (Estonia) and a Marie Curie Individual Fellowship-funded postdoctoral researcher at the University of Helsinki (Finland). She co-authored over 30 peer-reviewed publications on the antibacterial and immune effects of nanoparticles, including several highly cited publications. Dr. Bondarenko is also a co-founder of the biotechnological company Nanordica Medical, which focuses on developing advanced antibacterial nanotechnology.

#### **Fernando Torres And ´on**

Fernando Torres Andon is an AECC Researcher in Nanomedicine for cancer immunotherapy at ´ CiMUS, University of Santiago de Compostela, Spain. He is a pharmacist with a PhD in Molecular Biology, a postdoc in Nanotoxicology with Prof. Bengt Fadeel at Karolinska Institutet, Sweden, and a postdoc in Tumor Immunology with Prof. Paola Allavena at the Humanitas Institute, Italy. His current research at Alonso's lab (CiMUS) is focused on the development and evaluation of new nanostructures for the targeting and reprograming of tumor-associated macrophages into antitumor macrophages with the ability to kill tumor cells, inhibit angiogenesis and promote adaptive immune responses in solid tumors, with the ultimate goal of providing new solutions for patients with cancer.
